Pardeep K. Gupta Philadelphia College of Pharmacy University of the Sciences Philadelphia, PA 19104 • Recombinant DNA technology opened the doors for the use of proteinbased therapeutics • Limited success in the development of protein-based drugs is mainly due to • – Their low plasma circulation times and instability in the GI tract – Poor Patient compliance due to the need for frequent parenteral administration Hence a need for developing sustained release drug delivery systems for protein drugs Attractive option for delivering proteins because: High surface-to-volume ratio: enables high drug loading Possible to deliver drugs inside cells or even the nucleus Increased plasma circulation times Modulated release possible Active targeting is possible Disadvantages: Made of Polymers; represent hydrophobic surfaces for Proteins Protein Adsorption Spontaneous phenomenon; occurs when proteins encounter relatively hydrophobic surfaces Protein Unfolding occurs Loss of Protein Structure and Activity Inert hydrophilic surfaces (e.g. PEG Coated) prevent Protein Adsorption Modified Surfaces: Reversible Protein Adsorption http://what-when-how.com/nanoscience-and-nanotechnology/biosurfaces-water-structure-at-interfaces-part-1-nanotechnology/ Expression System E.Coli Physiological Significance Tissue differentiation , cell proliferation and protein synthesis in bones, cartilage, liver, immune system. Used in treatment for Short stature (pediatrics), Metabolic deficiencies, chronic renal failure, sepsis, burns Reasons for development of drug delivery systems: Daily dose injections, especially in pediatrics Molecular Weight: 22,000 Daltons, non-glycosylated Primary Structure: 191 amino acid peptide Secondary Structure: 4 alpha helices; 2 cysteine bonds Receptors: GHR and GHBPs; One hGH molecule binds to 2 membrane bound receptors to activate intracellular signals and biological activity Known Marketed Products: Humatrope, Genotropin, Norditropin Globular protein; single polypeptide chain of 191 amino acids Molecular weight is 22kDa; pI is 5.3; Two disulfide bonds- C53-C165 and C182-C189 Almost 55 +/- 5% of the polypeptide backbone exists in the right handed α-helical conformation 4 α-helical bundles form the architectural core of the protein and are surrounded by extended side chains and loop structures Absorption maxima is at 277nm Fluorescence properties are mainly due to Indole moiety of tryptophan and to a small extent due to tyrosine residues Literature studies show that substrate affinity is a very important factor in hGH adsorption Previous experiments in the lab have shown similar results: On hydrophobic surfaces hGH adsorption is considerably high, irreversible and associated with substantial structural change On hydrophilic surfaces hGH adsorption is relatively lower, maybe reversible to some extent & is associated with less structural changes Conditions of the micro-environment are significant Polystyrene Nanoparticles OUR PROJECT Recombinant Human Growth Hormone Can a surface be developed which interacts reversibly with r-hGH? Can a protein-coated surface serve this function successfully? Carboxyl-& Amino-functionalized Nanoparticles 5 Covalent Linkers: different end groups & Length Albumin-coated nanoparticles Lysozyme-coated Nanoparticles pH, Ionic Strength Studying Interactions of r-hGH: With the protein-coated Nanoparticles Casein-coated Nanoparticles A protein-coated colloidal surface was prepared & characterized to study its interactions with rhGH Determination of Surface bound proteins was attempted using traditional and modified BCA colorimetric assay Reversible r-hGH adsorption occurred due to the effect of following forces: Hydrophobic Surfaces Electrostatic forces Which of these forces would be the dominant driving force for rhGH adsorption/desorption was found to be influenced by the following characteristics of the new surface: Isoelectric point and net charge of surface bound protein pH and Ionic Strength of desorption Bio-conjugation linker used to tether model protein to surface Presence of 1% BSA in the desorption Amount of rhGH added for adsorption GHR: 620 amino acid protein, 246 aa extracellular domain in circulating form(GHBP); belongs to GH/Prolactin hematopoetic Class I cytokine receptor family GHBP-can act as agonist/antagonist depending on levels of GH, GHR turnover, post-receptor regulation of GHR and plasma GHBP levels. High affinity GHBP produced by proteolytic cleavage by TACE (receptor ectodomain shedding); 5-20% circulating GH binds to low affinity GHBPits precise nature is unknown GH at physiological conditions binds to GHBP in a 1:1 proportion; only at supraphysiological conditions the stoichiometry changes to 1:2 Deficiency of GHBP causes Laron Dwarfism; increased GHBP levels are seen in gonadal dysfunction; low levels are seen in Cirrhosis and diabetes Easy & Inexpensive production & characterization-e.g. BCA assay works! Eliminate tedious & expensive expression & purification procedures of proteins-Only the important parts of the protein chopped off & used GHBP peptides/fragments Natural carriers for GHBP; especially imp for GH replacement therapy where patients have inherent GHBP deficiency as well Peptides are smaller & hence more robust than proteins-storage & handling easier than proteins Biodegradable and porous Polymeric Shell such as PLGA to achieve sustained and/or controlled release G H GHBP fragment Subcutaneous/IV injection; ocular, nasal, transdermal delivery PLGA nanoparticle GHBP mutants were prepared using phGHbp and expressed in E.Coli KS330 The mutants were prepared using alanine-scanning mutagenesis. Concentrations were determined using UV absorbance and structure was determined using CD spectrophotometer Binding constants were determined from competitive displacement assays using I-125-labelled hGH as tracer Of residues 1-238 in hGHbp, removal of residues 7-28 does not affect binding 11 residues contribute significantly to hGH binding affinity (Arg43, Glu44, Ile103, Trp104,Ile105, Pro106, Asp126, Glu127, Asp164, Ile165 and Trp169). Many of these play indirect structural roles by supporting and positioning Trp104 and Trp169 for binding. On the other hand, side-chains in hGH act in a more independent fashion. The interface is composed mainly of side-chain interactions participating in aliphatic-aromatic stacking interactions. Binding surface on hGHbp is relatively “soft” and the binding determinants are on loops; in case of hGH they are on the loops and the surface is relatively “hard”. The main functional epitope is hydrophobic framed by polar residues to permit binding of only “correct” partners. Four segments in the cysteine-rich domain of the hGHbp that are important to binding of hGH These residues include Thr101 to Pro106>> Val125 to Asp132> Arg70 to Glu82 ~Glu42 to Glu44 There is electrostatic complementarity between an electropositive binding epitope on hGH and an electronegative epitope on hGHbp Of the 10 charged-to-alanine substitutions in the hGHbp causing reduction in binding affinity 7 are acidic residues. On the other hand on hGH 3 of the 5 disruptive binding sites are basic residues and none are acidic residues. Peptide No. Peptide Sequence Part of GHBP Sequence Naturally Occurring 1 S-P-E-R-E-T-F-S YES NO 2 R-R-N-T-Q-E-W-T-Q-E-W-K-E YES NO 3 R-R-N-T-Q-E YES NO 4 W-T-Q-E-W-K-E YES NO 5 T-S-I-W-I-P YES NO 6 V-D-E-I-V-Q-P-D YES NO 7 T-S-I-W-I-P-Y-C-I-G-K-C-F-S-V-D-E-IV-Q-P-D* NO NO 8 T-S-I-W-I-P-Y-G-S-V-D-E-I-V-Q-P-D NO NO 9 K-V-D-K-E-Y-E YES NO 10 R-V-R-S-K-Q-R YES NO *-Cysteine residues form a double bond Graduate students who worked on this project Snehal Atwe Rajeshwar Motheram Lisa Park Preeti Desai Ken Yin